BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. enGene’s lead investigational candidate, detalimogene voraplasmid (detalimogene) is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes
